(Q52603858)

1 July 2019

title

Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. (English)

1 reference

1 July 2019

author name string

Christine Lam

1

1 reference

1 July 2019

Ian D Ferguson

2

1 reference

1 July 2019

Margarette C Mariano

3

1 reference

1 July 2019

Yu-Hsiu T Lin

4

1 reference

1 July 2019

Megan Murnane

5

1 reference

1 July 2019

Hui Liu

6

1 reference

1 July 2019

Geoffrey A Smith

7

1 reference

1 July 2019

Sandy W Wong

8

1 reference

1 July 2019

Jack Taunton

9

1 reference

1 July 2019

Jun O Liu

10

1 reference

1 July 2019

Constantine S Mitsiades

11

1 reference

1 July 2019

Byron C Hann

12

1 reference

1 July 2019

Blake T Aftab

13

1 reference

1 July 2019

Arun P Wiita

14

1 reference

1 July 2019

publication date

5 April 2018

1 reference

1 July 2019

published in

Haematologica

1 reference

1 July 2019

volume

103

1 reference

1 July 2019

page(s)

1218-1228

1 reference

1 July 2019

issue

7

1 reference

1 July 2019

Interleukin-6 in human multiple myeloma.

cites work

1 reference

12 December 2020

JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells

1 reference

12 December 2020

Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma

1 reference

12 December 2020

Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation

1 reference

12 December 2020

Regulation of JAK-STAT signalling in the immune system

1 reference

12 December 2020

Characterization of in vitro growth of multiple myeloma cells

1 reference

12 December 2020

Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130.

1 reference

12 December 2020

MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification

1 reference

12 December 2020

Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo

1 reference

12 December 2020

Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation

1 reference

12 December 2020

KEA: kinase enrichment analysis

1 reference

12 December 2020

INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support

1 reference

12 December 2020

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

1 reference

12 December 2020

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

1 reference

12 December 2020

TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells

1 reference

12 December 2020

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

1 reference

12 December 2020

ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments

1 reference

12 December 2020

Differential expression analysis for sequence count data

1 reference

12 December 2020

The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival

1 reference

12 December 2020

The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.

1 reference

12 December 2020

Enrichment techniques employed in phosphoproteomics

1 reference

12 December 2020

Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis

1 reference

12 December 2020

Molecular pathogenesis of multiple myeloma and its premalignant precursor

1 reference

12 December 2020

Cancer drug discovery by repurposing: teaching new tricks to old dogs

1 reference

12 December 2020

Global cellular response to chemotherapy-induced apoptosis

1 reference

12 December 2020

Recent advances in drug repositioning for the discovery of new anticancer drugs

1 reference

12 December 2020

Pathogenesis beyond the cancer clone(s) in multiple myeloma

1 reference

12 December 2020

Janus Kinase Inhibitor Tofacitinib Shows Potent Efficacy in a Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS).

1 reference

12 December 2020

Enrichment Strategies in Phosphoproteomics

1 reference

12 December 2020

A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys

1 reference

12 December 2020

Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model

1 reference

12 December 2020

Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling

1 reference

12 December 2020

Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma

1 reference

12 December 2020

Enrichr: a comprehensive gene set enrichment analysis web server 2016 update

1 reference

12 December 2020

Can you teach old drugs new tricks?

1 reference

12 December 2020

Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth

1 reference

12 December 2020

Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice.

1 reference

12 December 2020

PANTHER version 11: expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements

1 reference

12 December 2020

The Drug Repurposing Hub: a next-generation drug library and information resource

1 reference

12 December 2020

JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.

1 reference

12 December 2020

Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.

1 reference

12 December 2020

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.

1 reference

12 December 2020

10.3324/HAEMATOL.2017.174482

Identifiers

DOI

1 reference

1 July 2019

release_6nk55k3b3bdv3mpgwimeghyynq

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6nk55k3b3bdv3mpgwimeghyynq

24 November 2022

mapped directly with Wikidata item

PMCID

6029548

1 reference

1 July 2019

PubMed ID

29622655

1 reference

1 July 2019